WO2009117567A3 - Substituted fullerenes as mri contrast agents - Google Patents

Substituted fullerenes as mri contrast agents Download PDF

Info

Publication number
WO2009117567A3
WO2009117567A3 PCT/US2009/037653 US2009037653W WO2009117567A3 WO 2009117567 A3 WO2009117567 A3 WO 2009117567A3 US 2009037653 W US2009037653 W US 2009037653W WO 2009117567 A3 WO2009117567 A3 WO 2009117567A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted fullerenes
substituted
sample
magnetic resonance
contrast agents
Prior art date
Application number
PCT/US2009/037653
Other languages
French (fr)
Other versions
WO2009117567A2 (en
Inventor
Russ Lebovitz
Original Assignee
Tego Biosciences Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tego Biosciences Corporation filed Critical Tego Biosciences Corporation
Publication of WO2009117567A2 publication Critical patent/WO2009117567A2/en
Publication of WO2009117567A3 publication Critical patent/WO2009117567A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Abstract

A contrast agent for enhancing contrast in in vivo magnetic resonance imaging, comprising a water-soluble, non-zero spin isotope-enriched substituted fullerene having a fullerene core or heterofullerene core and at least one substituent group bonded to at least one carbon of the fullerene core. A method of magnetic resonance imaging a sample, comprising (i) administering to the sample a plurality of substituted fullerenes; and (ii) detecting magnetic resonance signals from the sample. In the method, some or all of the plurality of substituted fullerenes may be non-zero spin isotope-enriched, but need not be. In the method, some or all of the plurality of substituted fullerenes may be hyperpolarized, but need not be.
PCT/US2009/037653 2008-03-20 2009-03-19 Substituted fullerenes as mri contrast agents WO2009117567A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3811008P 2008-03-20 2008-03-20
US61/038,110 2008-03-20
US4900208P 2008-04-30 2008-04-30
US61/049,002 2008-04-30

Publications (2)

Publication Number Publication Date
WO2009117567A2 WO2009117567A2 (en) 2009-09-24
WO2009117567A3 true WO2009117567A3 (en) 2010-02-25

Family

ID=40996605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/037653 WO2009117567A2 (en) 2008-03-20 2009-03-19 Substituted fullerenes as mri contrast agents

Country Status (1)

Country Link
WO (1) WO2009117567A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19808865A1 (en) * 1998-03-03 1999-09-09 Bayerl Production of crosslinked structures of colloidal dimensions, e.g. hollow spheres or films, useful as lubricants, drug delivery systems, contrast agents, therapy vectors, chromatograhic media, magnetic data storage coatings, etc.
US20030065206A1 (en) * 2001-10-01 2003-04-03 Bolskar Robert D. Derivatization and solubilization of insoluble classes of fullerenes
WO2005097807A2 (en) * 2004-03-26 2005-10-20 Luna Innovations Incorporated Pegylation and hydroxylation of trimetallic nitride endohedral metallofullerenes
WO2006009696A2 (en) * 2004-06-16 2006-01-26 Hematrope Pharmaceuticals Inc Anticoagulant contrast media
US20070025918A1 (en) * 2005-07-28 2007-02-01 General Electric Company Magnetic resonance imaging (MRI) agents: water soluble carbon-13 enriched fullerene and carbon nanotubes for use with dynamic nuclear polarization
WO2007070466A2 (en) * 2005-12-10 2007-06-21 The President And Fellows Of Harvard College In situ hyperpolarization of imaging agents
WO2007143558A1 (en) * 2006-06-01 2007-12-13 William Marsh Rice University Targeted nanostructures for cellular imaging

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19808865A1 (en) * 1998-03-03 1999-09-09 Bayerl Production of crosslinked structures of colloidal dimensions, e.g. hollow spheres or films, useful as lubricants, drug delivery systems, contrast agents, therapy vectors, chromatograhic media, magnetic data storage coatings, etc.
US20030065206A1 (en) * 2001-10-01 2003-04-03 Bolskar Robert D. Derivatization and solubilization of insoluble classes of fullerenes
WO2005097807A2 (en) * 2004-03-26 2005-10-20 Luna Innovations Incorporated Pegylation and hydroxylation of trimetallic nitride endohedral metallofullerenes
WO2006009696A2 (en) * 2004-06-16 2006-01-26 Hematrope Pharmaceuticals Inc Anticoagulant contrast media
US20070025918A1 (en) * 2005-07-28 2007-02-01 General Electric Company Magnetic resonance imaging (MRI) agents: water soluble carbon-13 enriched fullerene and carbon nanotubes for use with dynamic nuclear polarization
WO2007070466A2 (en) * 2005-12-10 2007-06-21 The President And Fellows Of Harvard College In situ hyperpolarization of imaging agents
WO2007143558A1 (en) * 2006-06-01 2007-12-13 William Marsh Rice University Targeted nanostructures for cellular imaging

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALL G. E. ET AL.: "Structural reassignement of the Mono- and Bis-Addition Products from the Addition Reactions of N-(diphenylmethylene)glycinate Esters to [60]Fullerene under Bingel conditions", J. ORG. CHEM., vol. 70, no. 24, 16 September 2005 (2005-09-16), XP007910747 *
MEIER M. ET AL.: "A 13C INADEQUATE and HF-GIAO Study of C60H2 and C60H6 Identification of Ring Currents in a 1,2-Dihydrofullerene", J. AM. CHEM. SOC., vol. 124, 10 July 2002 (2002-07-10), pages 8090 - 8094, XP007910752 *

Also Published As

Publication number Publication date
WO2009117567A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
WO2006054903A3 (en) Method of cardiac imaging with the use of hyperpolarized 13 c-pyruvate
Richard et al. Noncovalent functionalization of carbon nanotubes with amphiphilic Gd3+ chelates: toward powerful T1 and T2 MRI contrast agents
WO2005072780A3 (en) Cellular labeling for nuclear magnetic resonance techniques
WO2009036441A3 (en) Contrast agents
WO2008008075A3 (en) Magnetic resonance imaging (mri) agents: water soluble carbon-13 enriched fullerene and carbon nanotubes for use with dynamic nuclear polarization
WO2001074233A3 (en) Diffusion imaging of tissues
WO2011014648A3 (en) METHODS AND SYSTEM FOR DETECTING SOLUBLE AMYLOID-β
WO2010028013A3 (en) In vivo biofilm infection diagnosis and treatment
WO2006116021A3 (en) Mri technique based on electron spin resonance and endohedral contrast agent
WO2006120584A3 (en) Magnetic resonance imaging with short echo times
WO2009154425A3 (en) Multimodal imaging method using nano-emulsion comprising optical nano-particles and perfluorocarbons
WO2010056590A3 (en) Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging
WO2009129537A3 (en) Magnetic microstructures for magnetic resonance imaging
GB0022341D0 (en) Method
EP2113781A3 (en) Nuclear Magnetic Resonance apparatus
WO2008139480A3 (en) Assessment of blood-brain barrier disruption
WO2009105659A3 (en) Echo-decay-acceleration data acquisition method for gas identification using a low-field gradient
WO2009134435A3 (en) Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications
WO2002023209A3 (en) Mri method involving the use of a hyperpolarized contrast agent
WO2007115115A3 (en) Targeted mr imaging agents
WO2010107178A3 (en) Magnetic resonance imaging contrast agent with paramagnetic-inositol phosphates complexes
WO2009069051A3 (en) Non-spherical contrast agents for cest mri based on bulk magnetic susceptibility effect
WO2006086677A3 (en) Endohedral fullerenes as spin labels and mri contrast agents
WO2008087445A3 (en) Magnetic resonance imaging
WO2009117567A3 (en) Substituted fullerenes as mri contrast agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09721994

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 15/12/2010 AND 25/02/2011)

122 Ep: pct application non-entry in european phase

Ref document number: 09721994

Country of ref document: EP

Kind code of ref document: A2